Valion Bio Secures $7.7 Million in Latest Series B Funding Round
Valion Bio secured $7.7 million in its latest Series B, adding another data point to the FinTech funding market.
Series B$7.7 millionFinTechUndisclosed HQ
Valion Bio Raises $7.7 million in Funding
Valion Bio Raises $7.74 Million Via Series B/C Preferred and Warrants From 3i.
Investors Behind the Funding
The round was backed by 3i. Capvizr tracks this investor activity alongside sector momentum, co-investor patterns, and recent comparable raises.
Company Profile and Market Context
Valion Bio operates in FinTech. Valion Bio's financing adds to recent private-market activity.
Strategic Use of Funds
3i, LP under an $8.
Looking Ahead
Valion Bio Raises $7.74 Million Via Series B/C Preferred and Warrants From 3i
Source reference: original announcement/article.
View Valion Bio's full profile and funding history on Capvizr →